NXNN - Nexeon MedSystems Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
6.50
0.00 (0.00%)
At close: 9:40AM EDT
Stock chart is not supported by your current browser
Previous Close6.50
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume109
Market Cap12.777M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Nexeon Announces Submission for FDA Innovation Challenge

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announces that it has submitted an application in response to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder. Opioid Use Disorder (OUD), characterized by problematic symptoms of addiction to and withdrawal from opioids, is part of a public health crisis affecting more than 2 million Americans with significant physical, emotional, and cognitive impairment.

  • GlobeNewswire28 days ago

    Nexeon MedSystems Receives $830,000 grant from the National Institute of Neurological Disorders and Stroke

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced that it has received an $830,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant award, received through its wholly-owned subsidiary Nexeon MedSystems Puerto Rico Operations Company Corporation (“NMPROC”), will support the development of novel cloud-based software to improve programming for deep brain stimulation. The NINDS intends to fund $1.5 million over 3 years, subject to annual review and approval, with the remaining funds directed towards clinical evaluation of the software’s performance.

  • GlobeNewswire2 months ago

    Nexeon MedSystems Announces Second Quarter 2018 Financial Results

    Nexeon MedSystems Inc (”Nexeon”) (NXNN), a neurostimulation medical device company, announced today financial results for the second quarter of 2018. Nexeon completed two additional pre-submission interactions with the United States Food and Drug Administration (“FDA”) to determine the scope of requirements for approval of the Viant™ System for the Parkinson’s disease indication. Nexeon MedSystems Puerto Rico Operations Company Corporation (“NXPROC”), a wholly-owned subsidiary of Nexeon, received notification from the National Institute of Neurological Disorders and Stroke (NINDS) that it is conditionally approved for funding of an U44 Cooperative Agreement Award under the NIH BRAIN Initiative.

  • ACCESSWIRE10 months ago

    SeeThruEquity Issues Update on Nexeon MedSystems, Inc. (OTCQB: NXNN)

    NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • Nexeon MedSystems Provides Shareholder Update
    PR Newswire11 months ago

    Nexeon MedSystems Provides Shareholder Update

    Company to Host Conference Call November 20, 2017 4pm CST DALLAS , Nov. 20, 2017 /PRNewswire/ -- Nexeon MedSystems Inc. (OTCQB: NXNN, "Nexeon", "the Company"), is providing shareholders ...